Progress report on the potential of angiogenesis inhibitors for neuro-oncology (Q35964419)

11 August 2017

1 reference

title

Progress report on the potential of angiogenesis inhibitors for neuro-oncology (English)

1 reference

11 August 2017

main subject

angiogenesis inhibitor

1 reference

Benjamin Purow

1

1 reference

11 August 2017

Howard A Fine

series ordinal

2

1 reference

11 August 2017

publication date

1 January 2004

1 reference

11 August 2017

1 reference

11 August 2017

volume

22

1 reference

11 August 2017

issue

4

1 reference

11 August 2017

page(s)

577-587

1 reference

Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histological type: an analysis based on Surveillance, Epidemiology, and End Results (SEER) data, 1973-1991.

11 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200027141

Induction of angiogenesis during the transition from hyperplasia to neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200027141

Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200027141

Mechanisms of angiogenesis and arteriogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200027141

Vascular-specific growth factors and blood vessel formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200027141

High microvessel density in primitive neuroectodermal brain tumors of childhood

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200027141

Angiogenic profile of childhood primitive neuroectodermal brain tumours/medulloblastomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200027141

Descriptive analysis and quantification of angiogenesis in human brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200027141

Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200027141

Expression of vascular endothelial growth factor and its receptors in the anaplastic progression of astrocytoma, oligodendroglioma, and ependymoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200027141

Levels of vascular endothelial growth factor, hepatocyte growth factor/scatter factor and basic fibroblast growth factor in human gliomas and their relation to angiogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200027141

Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200027141

Organ targeting in vivo using phage display peptide libraries

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200027141

Non-invasive vascular imaging: assessing tumour vascularity

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200027141

Mechanism of action in thalidomide teratogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200027141

Antitumor activity of thalidomide in refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200027141

Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200027141

The mechanism of cancer-mediated conversion of plasminogen to the angiogenesis inhibitor angiostatin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200027141

Tumor invasion, proteolysis, and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200027141

Phase I clinical trial of oral COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200027141

Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200027141

Potentiation of cytotoxic cancer therapies by TNP-470 alone and with other anti-angiogenic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200027141

Combined effects of angiostatin and ionizing radiation in antitumour therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200027141

Combined treatment of a murine breast cancer model with type 5 adenovirus vectors expressing murine angiostatin and IL-12: a role for combined anti-angiogenesis and immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200027141

Synergy between an antiangiogenic integrin alphav antagonist and an antibody-cytokine fusion protein eradicates spontaneous tumor metastases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200027141

Comparative evaluation of the antitumor activity of antiangiogenic proteins delivered by gene transfer

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200027141

Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200027141

Antiangiogenic therapy of a recurrent giant cell tumor of the mandible with interferon alfa-2a.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200027141

Interferons alpha and beta down-regulate the expression of basic fibroblast growth factor in human carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200027141

Inhibition of angiogenesis in vivo by interleukin 12.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200027141

Interleukin-12 and interleukin-18 synergistically induce murine tumor regression which involves inhibition of angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200027141

The effect of selective cyclooxygenase-2 inhibitor on corneal angiogenesis in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200027141

A pilot trial of Vitaxin, a humanized anti-vitronectin receptor (anti alpha v beta 3) antibody in patients with metastatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200027141

Adenovirus-mediated delivery of a uPA/uPAR antagonist suppresses angiogenesis-dependent tumor growth and dissemination in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200027141

Adenovirus-mediated delivery of antiangiogenic genes as an antitumor approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200027141

Viral vector-mediated transduction of a modified platelet factor 4 cDNA inhibits angiogenesis and tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200027141

Therapeutic effects of viral vector-mediated antiangiogenic gene transfer in malignant ascites

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200027141

Local endostatin treatment of gliomas administered by microencapsulated producer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200027141

Continuous release of endostatin from microencapsulated engineered cells for tumor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200027141

Tumor regression by targeted gene delivery to the neovasculature

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200027141

Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200027141

Enhancement of tumor necrosis factor alpha antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13).

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200027141

21 January 2018

Identifiers

DOI

10.1081/CNV-200027141

1 reference

11 August 2017

1 reference